Michael A. Bookman, MD | Authors

21362 N 78th Ln




Salvage Therapy for Ovarian Cancer

June 01, 1998

As Drs. Sabbatini and Spriggs point out in their review, the majority of ovarian cancer patients continue to present with advanced-stage disease, and only a minority are cured after primary surgery and chemotherapy. At present, recurrent disease is best viewed as a chronic illness that requires ongoing management. A number of therapeutic options are available, but opportunities for cure remain limited. My comments will focus on post-remission therapy, small-volume residual disease, intraperitoneal therapy, secondary cytoreductive surgery, choice of second-line chemotherapy, and participation in phase II studies.